[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-or-metastatic-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-or-metastatic-ovarian-cancer":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100642622",false,"NCT07652073","A Study of DAT-2645 in Patients With BRCA1\u002F2 Mutations or HRD-Positive Ovarian Cancer","A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of DAT-2645 in Patients With BRCA1\u002F2 Deleterious Mutations or HRD-Positive Advanced\u002FMetastatic Ovarian Cancer","Inclusion Criteria:\n\n* sign a written informed consent form\n* At least 18 years of age (inclusive)\n* Epithelial ovarian cancer confirmed by histopathology or cytopathology\n* BRCA1\u002F2 mutation or HRD-positive status\n* Patients who have failed standard treatment or are unable to tolerate standard treatment\n* Patients must have received no more than five prior treatment lines\n* At least one measurable lesion\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Bone marrow reserve and organ function must meet the requirements\n* Negative result on a blood pregnancy test for a woman of childbearing age\n\nExclusion Criteria:\n\n* Received small-molecule chemotherapy or targeted therapy within 2 weeks or 5 half-lives prior to the first dose\n* Received treatment with an anticancer biological therapy within 4 weeks prior to the first dose\n* Underwent major surgery within 4 weeks prior to the first dose\n* Has previously received treatment with a PARG inhibitor\n* Inadequate response to previous PARP inhibitor maintenance therapy\n* With central nervous system metastases\n* Patients with clinically significant cardiovascular or cerebrovascular diseases\n* Uncontrolled active infections requiring intravenous antibiotics or hospitalization\n* Adverse reactions from prior anticancer therapy have not yet resolved to a grade ≤1","FEMALE","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645",[25],"Advanced or Metastatic Ovarian Cancer","NOT_YET_RECRUITING","2026-06-21",{"date":29,"type":30},"2026-06-25","ACTUAL",{"date":32,"type":19},"2026-06-15",{"date":34,"type":19},"2028-03-30",{"name":36,"class":37},"Danatlas Pharmaceuticals Co., Ltd","INDUSTRY",2,""]